What is Northland Capmk’s Estimate for BLFS FY2025 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk upped their FY2025 earnings estimates for shares of BioLife Solutions in a report issued on Friday, November 7th. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will post earnings per share of $0.07 for the year, up from their previous estimate of $0.05. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share.

BLFS has been the subject of a number of other reports. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Stephens assumed coverage on BioLife Solutions in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.29.

BioLife Solutions Trading Up 1.4%

BLFS opened at $26.29 on Monday. BioLife Solutions has a 1-year low of $19.10 and a 1-year high of $29.62. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -219.07 and a beta of 1.97. The company’s fifty day moving average price is $26.58 and its two-hundred day moving average price is $24.09.

Insiders Place Their Bets

In other BioLife Solutions news, CFO Troy Wichterman sold 1,032 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the completion of the sale, the chief financial officer owned 184,186 shares in the company, valued at approximately $4,941,710.38. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $25.53, for a total value of $255,300.00. Following the completion of the transaction, the chief marketing officer owned 124,618 shares in the company, valued at $3,181,497.54. The trade was a 7.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,307,742 shares of company stock worth $35,167,584 in the last ninety days. 2.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BLFS. Invesco Ltd. increased its position in shares of BioLife Solutions by 0.8% during the 2nd quarter. Invesco Ltd. now owns 3,580,778 shares of the medical equipment provider’s stock valued at $77,130,000 after purchasing an additional 29,724 shares during the last quarter. Vanguard Group Inc. grew its position in BioLife Solutions by 2.4% during the third quarter. Vanguard Group Inc. now owns 2,967,518 shares of the medical equipment provider’s stock valued at $75,701,000 after buying an additional 70,248 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in BioLife Solutions during the first quarter worth about $30,789,000. Ameriprise Financial Inc. raised its position in BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after acquiring an additional 109,959 shares during the period. Finally, Geode Capital Management LLC boosted its stake in BioLife Solutions by 3.8% in the second quarter. Geode Capital Management LLC now owns 921,105 shares of the medical equipment provider’s stock valued at $19,842,000 after acquiring an additional 33,849 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.